No association with disease outcome in relation to MUC1 IgG abs was observed in 199 patients with epithelial ovarian cancer randomized to the control arm in a phase III clinical trial evaluating intraperitoneal treatment with a radiolabelled murine anti-MUC1 MAb [77]. This evidence concerns the gene MUC1 and ovarian carcinoma.